Fractional CMO for Healthtech: Marketing Inside Regulatory Constraints

A fractional CMO for healthtech is a senior marketing executive who operates inside your business on a part-time or project basis, with the specific experience to market health products and services without breaching the regulatory frameworks that govern clinical claims, data privacy, and patient-facing communications.

This is the healthtech deep dive from our wider guide on what a fractional CMO does and when to hire one. If you are new to the fractional model, that guide covers the fundamentals. This post focuses on what makes healthtech marketing categorically different, and why the CMO you hire needs to understand that difference before they write a single word of copy.

Why Healthtech Marketing Is a Specialist Discipline

Healthtech marketing operates under a layer of regulatory scrutiny that most other industries simply do not face. Whether you are building a digital therapeutic, a patient engagement platform, a wearable device, or a clinical decision support tool, the claims you make in your marketing can trigger enforcement action from regulators including the Therapeutic Goods Administration (TGA) in Australia, the Food and Drug Administration (FDA) in the United States, and the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom.

These regulators do not draw a clean line between product claims and marketing claims. If your landing page says your app "helps manage Type 2 diabetes", that is a therapeutic claim. If your email campaign says your device "improves clinical outcomes", that is a therapeutic claim. The consequences of getting this wrong range from mandatory corrections and withdrawal of materials to formal enforcement, fines, and reputational damage at precisely the moment you are trying to build trust with clinicians and patients.

The practical implication is clear: a general-purpose CMO, however talented, is a genuine liability in this environment unless they have prior experience navigating regulated health markets. The cost of a misstep is rarely just a rewrite. It can delay a launch, freeze a funding round, or attract regulatory scrutiny that follows the company for years.

What a Fractional CMO for Healthtech Actually Does

A fractional CMO in healthtech owns your marketing strategy end-to-end, with the specific expertise to operate within clinical, regulatory, and ethical boundaries that would trip up a generalist.

In practical terms, this means they take responsibility for the following:

→ Developing a go-to-market strategy that accounts for your regulatory classification (SaMD, Class I/II/III device, prescription digital therapeutic, or general wellness product) and builds the marketing approach around what you are legally permitted to claim.

→ Writing or overseeing clinical messaging that is accurate, substantiated, and compliant with TGA, FDA, and MHRA guidance on therapeutic advertising.

→ Selecting channels and content formats that work for your audience, whether that is clinicians, health system procurement teams, patients, or consumers, without creating compliance exposure.

→ Building the internal marketing function, including hiring, agency briefing, and establishing a review process that keeps legal, regulatory affairs, and marketing aligned.

→ Owning the metrics that matter at your stage: awareness among target prescribers or health system buyers, pipeline from inbound content, conversion rates from trial to paid, and net revenue retention for SaaS health platforms.

They are an operating executive, owning outcomes and accountable for results. The engagement is part-time in hours, but the accountability is full-time in nature.

The Regulatory Landscape Your CMO Must Navigate

Understanding the regulatory environment your CMO will work inside is essential before you hire. The frameworks differ meaningfully by market, and a CMO who has only worked in one jurisdiction may create problems when you expand internationally.

In Australia, the TGA regulates therapeutic goods advertising under the Therapeutic Goods Act 1989 and the Therapeutic Goods Advertising Code. The TGA distinguishes between advertising to consumers and advertising to healthcare professionals, with different rules applying to each. The Australian Privacy Act 1988 and the My Health Records Act 2012 also govern how health data can be used in marketing contexts, including retargeting and personalisation.

In the United States, the FDA regulates promotional materials for medical devices and prescription products under 21 CFR Parts 801 and 807. The Federal Trade Commission (FTC) separately governs consumer-facing health claims and requires that efficacy claims be substantiated by competent and reliable scientific evidence. The Health Insurance Portability and Accountability Act (HIPAA) restricts how patient data can be used in marketing, including through third-party advertising platforms.

In the United Kingdom, the MHRA oversees medical device and medicine advertising. The Advertising Standards Authority (ASA) and the Committee of Advertising Practice (CAP) codes apply to consumer-facing health marketing. The Information Commissioner's Office (ICO) enforces UK GDPR compliance, which has specific implications for health data used in digital marketing.

A fractional CMO who has worked across these jurisdictions understands that a campaign cleared for the US market may require substantive revision before it runs in Australia or the UK. That cross-market fluency is often what separates a genuinely qualified candidate from one who simply has a strong general marketing record.

When Healthtech Companies Typically Need Fractional CMO Support

Most healthtech companies reach for fractional marketing leadership at one of four inflection points, and recognising which one applies to your business shapes the brief you give your CMO.

The first is pre-launch, when you have regulatory clearance approaching or recently granted and need to build the go-to-market strategy, messaging architecture, and channel plan from scratch. At this stage, the CMO is setting foundations, and the work is largely strategic with some execution oversight.

The second is post-Series A, when you have enough capital to invest in growth but not enough to justify a full-time CMO salary and the associated on-costs. At this stage, the CMO typically works two to three days per week, managing a small internal team and external agencies while reporting directly to the CEO or fractional CFO.

The third is international expansion, when you are entering a new market and need someone who understands the local regulatory and cultural context well enough to adapt your existing strategy rather than rebuild it from scratch. This is often a six to twelve month engagement with a clear scope.

The fourth is a pivot or repositioning, when your product classification has changed (for example, moving from a general wellness app to a regulated SaMD), your target buyer has shifted, or a regulatory decision has forced a change in how you can describe the product. A fractional CMO can lead the repositioning without the cost and disruption of replacing a full-time executive mid-flight.

What a Fractional CMO for Healthtech Costs

Fractional CMO engagements in healthtech typically carry a modest premium over general fractional CMO rates, reflecting the specialist regulatory knowledge required. The ranges below represent typical monthly retainer costs in 2026 for an experienced executive working two to three days per week.

In Australia, expect to pay between $12,000 and $20,000 per month (AUD) for a fractional CMO with genuine healthtech and regulatory experience. The standard fractional CMO range sits at $10,000 to $18,000/month (Glassdoor AU, 2025), and the healthtech premium reflects the narrower talent pool. A full-time CMO with comparable experience would cost $200,000 to $280,000 in base salary, with true employer cost reaching $250,000 to $380,000 per year once you include the 12% Superannuation Guarantee (ATO, effective 1 July 2025) and other on-costs.

In the United States, fractional CMO rates for regulated health markets typically run $10,000 to $25,000 per month (USD). The full-time CMO average sits at $225,908 (Built In, 2026), with total employer cost reaching $270,000 to $320,000 or more once benefits are included. The Bureau of Labor Statistics estimates benefit costs at approximately 29.7% above wages on average (BLS, September 2025).

In the United Kingdom, expect £7,000 to £18,000 per month (GBP) for a healthtech-experienced fractional CMO. A full-time CMO in the UK commands £160,000 to £220,000 in base salary (Glassdoor UK / Robert Walters, 2025), with employer National Insurance contributions running at 15% from April 2025 (HMRC, 2025/26), pushing total on-costs to 25 to 35% above base.

For a detailed breakdown of fractional executive costs by market, see our dedicated cost pages for Australia, the United States, and the United Kingdom.

How to Evaluate a Fractional CMO's Regulatory Competence

Most candidates will claim regulatory awareness. Fewer will have genuinely operated inside it. The interview process needs to surface the difference.

Ask the candidate to walk you through a campaign they built for a regulated health product. Specifically, ask them how they handled the claims review process, which internal or external parties were involved, and what they changed as a result. A candidate with real experience will give you a specific, slightly complicated answer. A candidate who has read about the topic will give you a general one.

Ask them to review a piece of your existing marketing material and identify any claims that could attract regulatory attention. This is a practical test with a clear pass/fail signal. If they do not flag anything on a piece that your legal or regulatory affairs team has concerns about, that tells you something important.

Ask them about their experience with your specific product classification. The marketing constraints for a Class II medical device are different from those for a general wellness app, which are different again from those for a prescription digital therapeutic. A CMO who conflates these categories has not worked deeply enough in the space.

At Fractionus, we accept fewer than 3% of executive applicants onto the platform. Every CMO in our network has been assessed not just on marketing capability but on the specific industry and regulatory contexts they have operated in. You can read more about how we vet our executives and what that process involves.

Building the Engagement for Success

A fractional CMO engagement in healthtech works best when the scope is clear, the access is real, and the internal review process is fast enough to let marketing move.

On scope: be specific about what the CMO owns versus what they advise on. If they are responsible for pipeline generation, they need authority over channel spend and agency selection. If they are responsible for brand positioning, they need access to clinical and regulatory leadership to pressure-test messaging before it goes to market. Ambiguity about ownership creates friction that costs time and money.

On access: fractional executives work part-time in hours, but they need the same quality of information access as a full-time hire. That means being in the room (or on the call) for product decisions that affect positioning, having a direct line to the CEO, and receiving honest commercial data including what is working and what is not.

On review process: the single biggest drag on healthtech marketing velocity is a slow or unclear internal approval process for content and campaigns. Before your fractional CMO starts, map the review chain. Who needs to sign off on consumer-facing claims? What is the turnaround expectation? A CMO who produces strong work but cannot get it through internal review in time to matter is an expensive frustration for everyone involved.

Finally, consider the relationship between your fractional CMO and any fractional or full-time CFO in the business. Marketing investment decisions in healthtech often intersect with regulatory affairs budgets, clinical evidence generation costs, and investor relations. A CMO and CFO who communicate well can align on where commercial investment makes the most sense at each stage of the regulatory and commercial journey.

If you are ready to find a fractional CMO who understands how to market inside regulatory constraints, tell us what you need at Fractionus and we will have a shortlist of vetted candidates to you within 2 to 5 days.

Frequently Asked Questions

What does a fractional CMO for healthtech actually do?

A fractional CMO for healthtech owns the marketing strategy and execution for a health technology company on a part-time basis, typically two to three days per week. Their responsibilities include go-to-market planning, clinical messaging, channel strategy, team building, and agency management, all within the regulatory frameworks governing therapeutic claims in their target markets. They operate as a senior executive with full accountability for marketing outcomes, at a fraction of the cost of a full-time hire.

How much does a fractional CMO for healthtech cost?

A fractional CMO for healthtech typically costs $12,000 to $20,000 per month in Australia (AUD), $10,000 to $25,000 per month in the United States (USD), and £7,000 to £18,000 per month in the United Kingdom (GBP). These ranges reflect the specialist regulatory knowledge required in health markets and sit modestly above standard fractional CMO rates. The cost compares favourably to a full-time CMO, whose total employer cost in these markets typically exceeds $300,000 per year once salary, superannuation or benefits, and on-costs are included.

What regulatory frameworks does a healthtech CMO need to understand?

A fractional CMO for healthtech operating in Australia needs to understand TGA advertising rules under the Therapeutic Goods Advertising Code and privacy obligations under the Australian Privacy Act 1988. In the United States, the relevant frameworks include FDA promotional regulations under 21 CFR, FTC substantiation requirements for health claims, and HIPAA restrictions on using patient data in marketing. In the United Kingdom, the MHRA, ASA/CAP codes, and ICO guidance under UK GDPR all apply to health marketing activities.

When should a healthtech company hire a fractional CMO?

A healthtech company should consider hiring a fractional CMO when approaching regulatory clearance and preparing for commercial launch, after a Series A raise when growth investment is available but a full-time CMO salary is premature, when entering a new international market with different regulatory requirements, or when repositioning a product whose classification or target audience has changed. In each case, the fractional model provides senior marketing leadership at a cost that matches the company's current stage.

Can a fractional CMO for healthtech work across multiple markets simultaneously?

Yes, a fractional CMO for healthtech can manage multi-market strategies, provided they have genuine experience in each jurisdiction's regulatory framework. The most effective approach is to hire a CMO with cross-market experience (typically Australia, the US, and the UK) who can adapt a core strategy to each market's specific compliance requirements rather than building separate strategies from scratch. This is a meaningful efficiency advantage compared to hiring separate marketing leadership in each market.

How is a fractional CMO different from a marketing consultant in healthtech?

A fractional CMO operates as an embedded member of your leadership team, owning outcomes and managing people, budgets, and agencies directly. A marketing consultant typically delivers advice, a strategy document, or a specific project output, then exits. In healthtech, the distinction matters because regulatory compliance in marketing is an ongoing operational responsibility, not a one-time deliverable. A fractional CMO stays accountable for the work as it moves through review, launch, and iteration.

How quickly can Fractionus match a healthtech company with a fractional CMO?

Fractionus delivers a shortlist of vetted fractional CMOs within 2 to 5 days of receiving a brief. Every CMO on the platform has passed a rigorous vetting process that accepts fewer than 3% of applicants, and the matching process accounts for industry-specific experience including regulated health markets. This means healthtech companies receive candidates who have already been assessed for the regulatory competence the role requires, rather than discovering gaps during the interview process.